KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The distal nephron biomarkers associate with diabetic kidney disease progression.

Christina L Tamargo, Steven G Coca, Heather Thiessen Philbrook, David G Hu, Joachim H Ix, Michael G Shlipak, Linda F Fried, Orlando M Gutierrez, Sushrut S Waikar, Sarah J Schrauben, Jeffrey R Schelling, Peter Ganz, Paul L Kimmel, Jason H Greenberg, Rajat Deo, Ayumi Takakura, Ramachandran S Vasan, Joseph V Bonventre, Chirag R Parikh

JCI Insight 10(12) e186836

PMID40548378
PMCIDPMC12220953
DOI10.1172/jci.insight.186836
发表日期2025-06-23
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

UNLABELLED: BACKGROUNDWhile urinary biomarkers show promise in predicting diabetic kidney disease (DKD) progression, distal tubular markers remain understudied. We investigated the association of distal tubule markers, epidermal growth factor (EGF) and uromodulin (UMOD), with DKD progression in the Veterans Affairs Diabetes in Nephropathy (VA NEPHRON-D) clinical trial. METHODS: We used Cox regression models to evaluate the association between each biomarker and DKD progression and the relationship between change over time in biomarker and DKD progression. We used mixed models to investigate biomarker levels at baseline, 12 months, and over time and their relationships with longitudinal eGFR change. RESULTS: Participants (n = 1,116) had type 2 diabetes, urine albumin-to-creatinine ratio (UACR) ≥ 300 mg/g, and eGFR 30-89.9 mL/min/1.73 m2. Mean age was 65 years, mean eGFR was 56 (SD 19) mL/min/1.73 m2, and median UACR was 840 (IQR 424-1,780) mg/g. One hundred forty-four participants (13%) had DKD progression over a median follow-up of 2.2 (1.3-3.1) years. Higher baseline EGF and UMOD were independently associated with a lower risk of DKD progression (adjusted HR 0.68, 95% CI 0.47, 0.99 and 0.85, [0.75, 0.98] per 2-fold higher concentration of EGF and UMOD, respectively). Serial biomarker measurements were performed at baseline and 12 months, and a slower decline in biomarkers was associated with a lower risk of DKD progression when adjusted for baseline biomarker levels. CONCLUSION: Urinary EGF and UMOD may serve as valuable prognostic biomarkers in DKD. CLINICALTRIALS: gov NCT00555217. FUNDING: NIH U01DK102730, U01DK103225, K23 DK118198, R01DK137087, U01DK103225, R37DK039773, U01DK114866, U01DK106962, U01DK129984, and R01DK093770; National Institute of Diabetes and Digestive and Kidney Diseases contract U01DK106965.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Relationship between baseline urine biomarker levels and hazard of DKD progression. Splines are truncated to the 2.5 th and 97.5 th percentiles, representing 95% of the data. Splines are unadjusted. EGF, epidermal growth factor; UMOD, uromodulin.
非 KM Figure
Figure 2Figure 2. Relationship between 12-month urine biomarker levels and hazard of DKD progression. Splines are truncated to the 2.5 th and 97.5 th percentiles, representing 95% of the data. Splines are unadjusted. EGF, epidermal growth factor; UMOD, uromodulin.
非 KM Figure